A research center's experience of T-cell redirecting therapies in triple-class refractory multiple myeloma.
Puertas B, Fernández-Sánchez A, Alejo E, Rey-Bua B, Martín-López AÁ, Pérez López E, Lopez-Parra M, Lopez-Corral L, Gutierrez NC, García-Sanz R, Puig N, Gonzalez-Calle V, Mateos MV.
Puertas B, et al. Among authors: fernandez sanchez a.
Blood Adv. 2024 May 8:bloodadvances.2024012773. doi: 10.1182/bloodadvances.2024012773. Online ahead of print.
Blood Adv. 2024.
PMID: 38717869